Preferred Label : Lemzoparlimab;
NCIt synonyms : Anti-CD47 Monoclonal Antibody TJC4;
NCIt definition : A human monoclonal antibody targeting the human cell surface antigen CD47, with potential
phagocytosis-inducing and antineoplastic activities. Upon administration, lemzoparlimab
preferentially binds to a unique epitope of CD47 on tumor cells. This blocks the interaction
of CD47 with signal regulatory protein alpha (SIRPalpha), an inhibitory protein expressed
on macrophages and dendritic cells (DCs), which prevents CD47/SIRPalpha-mediated signaling
and abrogates the CD47/SIRPalpha-mediated inhibition of phagocytosis. This induces
pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically
expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related
protein (LRP), expressed on macrophages, which results in macrophage activation and
the specific phagocytosis of tumor cells. Additionally, blocking CD47 signaling activates
an anti-tumor T-lymphocyte immune response and T-cell-mediated killing of CD47-expressing
tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated
antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSCs) and overexpressed
on the surface of a variety of cancer cells. Expression of CD47, and its interaction
with SIRPalpha, leads to the inhibition of macrophage activation and protects cancer
cells from phagocytosis, which allows cancer cells to proliferate. TJC4, compared
to other anti-CD47 monoclonal antibodies, is designed to minimize inherent binding
to normal red blood cells (RBCs), which may results in a more advantageous hematologic
safety profile.;
UNII : 0H2XLR2IKW;
CAS number : 2377483-71-9;
Molecule name : TJC4; TJ 011133; TJ-011133;
NCI Metathesaurus CUI : CL977248;
Origin ID : C163977;
UMLS CUI : C5554570;
Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
